BRAF and neoplasm: The OS after initial treatments for recurrences was 22 and 24 months, respectively, in 2 patients with BRAF mutants, 50 months in 1 patient with the KRAS mutation and 50 months in 1 patient with wild types of both genes in the primary tumour (50 months in the 2 patients with the KRAS mutation in the ovarian metastases).